Will the price of oil collapse this year? Investors are worried they will and that could push refiners like�Phillips 66 (PSX) and PBF Energy (PBF) higher.
Bloomberg NewsHoward Weil’s Blake Fernandez and Richard Roberts explain:
We are witnessing a rotation from U.S. centric Independent E&P�� toward Independent Refiners in an effort to hedge the risk of collapsing domestic crude prices. From a global perspective, macro [refining & marketing] dynamics are improving into ��4 with significant crude supply growth placing a theoretical ceiling on oil prices / feedstock costs while underlying demand growth remains intact thereby supporting product prices…
That said we are recommending a slight tactical shift toward more defensive posturing with a focus on lower beta names and companies that screen at a discount from a valuation perspective. As a result, we are
downgrading [Delek US Holdings (DK)] and [Tesoro (TSO)] to Sector Perform and upgrading [Phillips 66] and [PBF Energy] to Sector Outperform.
Top 5 Media Companies To Buy Right Now: Roche Holding AG (RHHBY)
Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. The Company belongs to the Roche Group that operates through numerous subsidiaries and associated companies located around the world. The Company�� products and services cover every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Roche operates through two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. The Company�� Diagnostics Division includes five sub-divisions: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan. In March 2009, the Company completed the acquisition of Genentech, Inc. In March 2010, the Company acquired assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow.
During the year ended December 31, 2008, the Company Pharmaceuticals Division marketing gained approvals for its rheumatoid arthritis medicine Actemra/RoActemra in Japan, Switzerland and the European Union. In 2008, the division initiated 12 new phase III projects in, including clinical trials of the compounds pertuzumab, for breast cancer; taspoglutide, for type two diabetes, and dalcetrapib, for cardiovascular risk reduction. As of December 31, 2008, the Pharmaceuticals Division filed 11 major new marketing applications and gained 13 major regulatory approvals. At the beginning of 2009, the division�� research and development pipeline comprised 120 clinical projects, including 62 new molecular entities (NMEs) and 58 additional indications. Forty NMEs are in phase I, 16 in phase II and six in phase III or f! iled for regulatory review.
In 2008, Roche Pharmaceuticals signed a total of 57 new agreements including seven product transactions and 43 research and technology collaborations. In May 2008, Roche acquired Piramed Limited, a UK company with therapeutic research programmes targeting the PI3-kinase pathway in oncology and inflammatory disease. In June 2008, signed licensing agreement with ThromboGenics and BioInvent for their jointly developed anticancer agent TB-403 (R7334). In September, 2008, the Company acquired Mirus Bio Corporation active in the field of ribonucleic acid interference (RNAi) delivery and completed the acquisition of ARIUS Research Inc., which has a antibody platform that identifies and selects antibodies based on their functional ability to affect disease. S Research Inc. In January 2009, Roche acquired Memory Pharmaceuticals, which develops drug candidates for the treatment of debilitating central nervous system disorders such as Alzheimer�� disease and schizophrenia.
Pharmaceuticals
Within Pharmaceuticals division, the Company is engaged in the provision of drugs the areas of oncology, anemia, cardiovascular diseases, central nervous system, infectious diseases, inflammatory and autoimmune diseases, metabolic disorders, cancer, transplantation and virology. The products offered by Roche�� Pharmaceuticals division include MabThera/Rituxan, Herceptin, Avastin, Tamiflu, CellCept, NeoRecormon, Epogin, Pegasys, Tarceva, Xeloda, Bonviva, Boniva, Lucentis, Tamiflu, Xolair, Valcyte, Cymevene, Xenical, Pulmozyme, Nutropin, Neutrogin, Rocephin, Activase, TNKase and Madopar. The products offered by the Pharmaceuticals division are sold in seven geographic regions: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan.
Diagnostics
Roche�� Diagnostics Division is a supplier of in vitro diagnostics (IVDs). Its products are used to test body fluids a! nd tissue! samples to obtain information for the purpose of preventing, diagnosing, treating and monitoring disease. The Company has business areas five within the diagnostics division: Professional Diagnostics, Diabetes Care, Tissue Diagnostics, Molecular Diagnostics and Applied Science. Roche�� Diagnostics division provides IVD services, including centralized laboratory testing and point-of-care diagnostics to molecular diagnostics and diabetes self management. In addition, it supplies research tools to life scientists.
Roche Professional Diagnostics supplies instrument systems, tests, software and services. It provides point-of-care testing products to support clinical decision-making close to the patient, in doctors��offices, emergency rooms and other primary and specialty care settings. Twelve Serum Work Area assays were rolled out during the year ended December 31, 2008, across Europe and in other markets. New assays included the Elecsys anti-TSH receptor antibody assay for the diagnosis of Graves��disease the Elecsys anti-CCP antibody assay, a test to aid the diagnosis of rheumatoid arthritis, and the Roche Cystatin C clinical chemistry test for early detection of impaired kidney function, among others. Roche Diabetes Care�� products portfolio covers the entire diabetes self-management spectrum, from glucose monitoring to insulin delivery, as well as monitoring systems with integrated lancets and test strips software for storing and analyzing data. Roche Tissue Diagnostics develops and manufactures medical diagnostic instruments and reagent systems that provide automation technology for use in the diagnosis and prognosis of cancer and infectious disease. In 2008 Roche Tissue Diagnostics launched ofhe Bench- Mark Ultra, a system that performs immunohistochemistry and in situ hybridisation testing simultaneously on a single continuous and random access platform. Roche Molecular Diagnostics develops and commercializes diagnostic and blood screening platforms and tests based on Roche�� ! real-time! polymerase chain reaction (PCR) technology. Applied Science business area supplies a specific reagents and test kits for use in life sciences encompassing biology, biotechnology ,medical research, as well as disease areas like cancer and virology. Applied Science�� business area product portfolio includes such sequencing systems as LightCycler 480, LightCycler 480 II, GS FLX Titanium. In addition, Applied Science offers xCELLigence cell analyzer.
Advisors' Opinion:- [By Dan Carroll]
Alexion Pharmaceuticals (NASDAQ: ALXN ) posted a much better week for investors, as the orphan disease-treating company's shares jumped 18.5% over the past five days. In the biotech world, buyout rumors are hype-worthy events -- and Alexion's right in the center of one, as Big Pharma's Roche (NASDAQOTH: RHHBY ) is reportedly looking into adding the company to its ranks, according to sources listed by Reuters.
- [By Keith Speights]
Considerable speculation also centered around the possibility that Roche� (NASDAQOTH: RHHBY ) could entertain an offer. Roche had previously pursued an acquisition of Life's rival Illumina (NASDAQ: ILMN ) . However, the potential deal broke down because Illumina wanted a price higher than what Roche was willing to pay. Roche's chairman made comments then that strongly hinted the company could go after another target. Life Technologies seemed to be a strong possibility.
- [By James E. Brumley]
I hate to be the one to say I told you so, but, I told you so. Back on February 26th I suggested IsoRay, Inc. (NYSEMKT:ISR) shares were a budding breakout play. The 48% rally that's played out for ISR in the meantime unfurled right on cue. While overbought in the very short run, this small cap stock looks like it's earning the right to be compared to the likes of bigger brothers in the cancer-treatment space... names like Roche Holding Ltd. (OTCMKTS:RHHBY) or Theragenics Corporation (NYSE:TGX).
- [By Sean Williams]
Dendreon's likely partner
While it's purely speculation on my part, I believe the most likely marketing partner would be one of Europe's premier cancer-fighting companies, Roche (NASDAQOTH: RHHBY ) .
Hot Defensive Companies To Invest In 2014: Aerosonic Corporation(AIM)
Aerosonic Corporation, together with its subsidiaries, engages in the design, manufacture, and sale of aircraft instruments worldwide. It offers mechanical and digital altimeters, airspeed indicators, rate of climb indicators, microprocessor controlled air data test sets, and other flight instruments. The company also produces mechanical and electro-mechanical cockpit instruments, angle of attack stall warning systems, digital cockpit instruments, integrated flight display systems, aircraft sensors and monitoring systems, and integrated multifunction probes, such as integrated air data sensors. It markets its products to manufacturers of corporate and private jets, contractors of military jets, the United States government, and private aircraft owners. The company sells its products directly through its sales personnel, as well as through distributors and commissioned sales representatives who resell to aircraft operators. Aerosonic Corporation was founded in 1953 and is b ased in Clearwater, Florida.
Advisors' Opinion:- [By Katia Dmitrieva]
Aimia (AIM) Inc.�� decision to move its Aeroplan reward-partnership to Toronto-Dominion (TD) Bank is a blow to Canadian Imperial Bank of Commerce, which stands to lose customers and as much as C$3 billion ($2.9 billion) in credit-card balances.
Hot Defensive Companies To Invest In 2014: Zinco Do Brasil Inc (ZNBR)
Zinco do Brasil Inc., formerly TurkPower Corporation, incorporated on November 4, 2004, has been a Turkish-American consulting and service operations firm and junior mining company. TurkPower offered its domestic and international clients consulting services and plans to act as a full service operator for wind, hydro, solar, coal and geothermal energy parks in Turkey.
In November 2011, the Company ceased all operations in Turkey. During the fiscal year ended May 31, 2012 (fiscal 2012) the Company impaired its entire mining company investment.
Advisors' Opinion:- [By Peter Graham]
Small cap mining stocks Discovery Minerals Ltd (OTCMKTS: DSCR), Zinco Do Brasil Inc (OTCMKTS: ZNBR) and Amalgamated Gold and Silver Inc (OTCMKTS: BCHS) have been getting some extra attention lately as one stock surged last Friday while the other two are or have been in the past, the subject of paid promotions. It goes without saying though that small cap mining stocks tend to be riskier than your average stock. But do these three small cap mining stocks have what it takes to produce a mother lode for investors? Here is a deeper dig into all three:
Hot Defensive Companies To Invest In 2014: Transcananda Pipelines Ltd.(TRP)
Transcanada Corporation operates as an energy infrastructure company in North America. The company operates in three segments: Natural Gas Pipelines, Oil Pipelines, and Energy. The Natural Gas Pipelines segment develops and operates energy infrastructure, including natural gas pipelines and regulated gas storage facilities. Its network of natural gas pipelines extends approximately 60,000 km tapping into gas supply basins in North America. The Oil Pipelines segment operates Keystone crude oil pipeline system, which includes completed 3,467 km Wood River/Patoka and Cushing Extension phases, and the proposed 2,673 km U.S. Gulf Coast Expansion. The Energy segment engages in the acquisition, development, construction, ownership, and operation of electrical power generation plants; the purchase and marketing of electricity; the provision of electricity account services to energy and industrial customers; and the development, construction, ownership, and operation of non-regulat ed natural gas storage in Alberta. The company was founded in 1951 and is headquartered in Calgary, Canada.
Advisors' Opinion:- [By Tyler Crowe]
Despite the obvious fundamental advantages of increased trade of oil between the two countries, there are still some major political hurdles to conquer. On the Canada-to-U.S. side of the argument, TransCanada's (NYSE: TRP ) Keystone XL pipeline has been stuck in litigation for several months. The proposed pipeline has the potential to deliver 830,000 barrels per day of oil to refineries in the Gulf of Mexico, a region that is capable of refining about 2.3 million barrels per day of heavy sour crude. The problem, however, is that the pipeline is receiving stiff opposition from political groups over environmental concerns. Other pipelines such as Enbridge's (NYSE: ENB ) Mainline and Energy Transfer Partner's (NYSE: ETP ) Trunkline Reversal project have also met some opposition over similar concerns to Keystone XL, but they certainly have not seen as much media attention.
- [By Aaron Levitt]
Tapping the full potential of that abundance is expensive and hinges on various logistic projects — like approving TransCanada�� (TRP)�Keystone XL pipeline. But analysts at the International Energy Agency (IEA) estimate that the opportunity is just too big for Canada to ignore, and that oil sands production will surge to a staggering 5.7 million barrels per day by 2030. This jump in production will make Canada the fourth-fastest growing oil player on the planet.
Hot Defensive Companies To Invest In 2014: PDC Energy Inc (PDCE)
PDC Energy, Inc. (PDC), incorporated on March 25, 1955, doing business as PDC Energy, is a domestic independent exploration and production company, which acquires, develops, explores, and produces natural gas, natural gas liquids (NGLs), and crude oil. Its Western Operating Region is focused on development in the Wattenberg Field in Colorado, particularly in the liquid-rich horizontal Niobrara play and on the ongoing development of refractures and recompletions of its Wattenberg wells. In its Eastern Operating Region, it is focused on development activity in the liquid-rich portion of the Utica Shale play in Ohio. The Company owns an interest in approximately 7,200 gross producing wells and maintained an average production rate of 135.6 One million cubic feet of natural gas volume (MMcfe) per day for the year ended December 31, 2012, which was comprised of 65.3% natural gas, 10.2% NGLs and 24.5% crude oil. It divides its operating activities into two segments: Oil and Gas Exploration and Production, and Gas Marketing. It divides its Western Operating Region into two areas: the Wattenberg Field and Piceance Basin. On February 28, 2012, the Company divested its Permian Basin assets. In May 2012, it announced that it has executed a definitive agreement to acquire Core Wattenberg assets that contain liquid-rich horizontal drilling opportunities. The effective date of the transaction is April 1, 2012. The assets are located in the Core Wattenberg Field of Weld and Adams Counties, Colorado and are approximately 94%-operated. The acquired assets include an estimated 35,000 net acres prospective for horizontal development of the Niobrara and Codell formations. In July 2012, the Company acquired core Wattenberg assets. In September 2012, Miller Energy Resources, Inc. acquired its Tennessee assets. On June 18, 2013, PDC Energy Inc announced that it has sold its non-core Colorado natural gas assets.
Oil and Gas Exploration and Production
The Company�� Oil and Gas Exploration and Prod! uction segment reflects revenues and expenses from the production and sale of natural gas, NGLs and crude oil. It sells its natural gas to marketers, utilities, industrial end-users and other wholesale purchasers. It sells natural gas, which it produces under contracts with indexed or New York Mercantile Exchange (NYMEX) monthly pricing provisions with the remaining production sold under contracts with daily pricing provisions. Its contracts include provisions wherein prices change monthly with changes in the market, for which adjustments may be made based on whether a well delivers to a gathering or transmission line, quality of natural gas and prevailing supply and demand conditions. It does not refine any of its crude oil production. It sells its crude oil to oil marketers and refiners. Its crude oil production is sold to purchasers at or near its wells under both short and long-term purchase contracts with monthly pricing provisions based on an average daily price. Its NGLs are sold to one NGL marketer in the Wattenberg Field. Its NGL production is sold under both short and long-term purchase contracts with monthly pricing provisions based on an average daily price.
The Company�� Oil and Gas Exploration and Production segment also reflects revenues and expenses related to well operations and pipeline services. It is paid a monthly operating fee for the portion of each well it operates that is owned by others, including its affiliated partnerships. It constructs, owns and operates gathering systems in its areas of operations. Its natural gas and NGLs are transported through its own and third party gathering systems and pipelines. It enters into firm transportation agreements to provide for pipeline capacity to flow and sell a portion PDC Energy, Inc. (PDC), incorporated on March 25, 1955, doing business as PDC Energy, is a domestic independent exploration and production company, which acquires, develops, explores, and produces natural gas, natural gas liquids (NGLs), and crude oil. Its! Western ! Operating Region is focused on development in the Wattenberg Field in Colorado, particularly in the liquid-rich horizontal Niobrara play and on the ongoing development of refractures and recompletions of its Wattenberg wells. In its Eastern Operating Region, it is focused on development activity in the liquid-rich portion of the Utica Shale play in Ohio. The Company owns an interest in approximately 7,200 gross producing wells and maintained an average production rate of 135.6 One million cubic feet of natural gas volume (MMcfe) per day for the year ended December 31, 2012, which was comprised of 65.3% natural gas, 10.2% NGLs and 24.5% crude oil. It divides its operating activities into two segments: Oil and Gas Exploration and Production, and Gas Marketing. It divides its Western Operating Region into two areas: the Wattenberg Field and Piceance Basin. On February 28, 2012, the Company divested its Permian Basin assets. In May 2012, it announced that it has executed a definitive agreement to acquire Core Wattenberg assets that contain liquid-rich horizontal drilling opportunities. The effective date of the transaction is April 1, 2012. The assets are located in the Core Wattenberg Field of Weld and Adams Counties, Colorado and are approximately 94%-operated. The acquired assets include an estimated 35,000 net acres prospective for horizontal development of the Niobrara and Codell formations. In July 2012, the Company acquired core Wattenberg assets. In September 2012, Miller Energy Resources, Inc. acquired its Tennessee assets.
Oil and Gas Exploration and Production
The Company�� Oil and Gas Exploration and Production segment reflects revenues and expenses from the production and sale of natural gas, NGLs and crude oil. It sells its natural gas to marketers, utilities, industrial end-users and other wholesale purchasers. It sells natural gas, which it produces under contracts with indexed or New York Mercantile Exchange (NYMEX) monthly pricing provisions with the remaining p! roduction! sold under contracts with daily pricing provisions. Its contracts include provisions wherein prices change monthly with changes in the market, for which adjustments may be made based on whether a well delivers to a gathering or transmission line, quality of natural gas and prevailing supply and demand conditions. It does not refine any of its crude oil production. It sells its crude oil to oil marketers and refiners. Its crude oil production is sold to purchasers at or near its wells under both short and long-term purchase contracts with monthly pricing provisions based on an average daily price. Its NGLs are sold to one NGL marketer in the Wattenberg Field. Its NGL production is sold under both short and long-term purchase contracts with monthly pricing provisions based on an average daily price.
The Company�� Oil and Gas Exploration and Production segment also reflects revenues and expenses related to well operations and pipeline services. It is paid a monthly operating fee for the portion of each well it operates that is owned by others, including its affiliated partnerships. It constructs, owns and operates gathering systems in its areas of operations. Its natural gas and NGLs are transported through its own and third party gathering systems and pipelines. It enters into firm transportation agreements to provide for pipeline capacity to flow and sell a portion
Advisors' Opinion:- [By Garrett Cook]
Energy shares dropped around 0.22 percent in today’s trading. Top decliners in the sector included Daqo New Energy (NYSE: DQ), PDC Energy (NASDAQ: PDCE), and YPF SA (NYSE: YPF).
- [By Seth Jayson]
PDC Energy (Nasdaq: PDCE ) reported earnings on May 1. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), PDC Energy whiffed on revenues and beat expectations on earnings per share.
Hot Defensive Companies To Invest In 2014: ADVA Optical Networking SE (ADV)
ADVA Optical Networking SE is a Germany-based company that develops, manufactures and sells optical and Ethernet-based networking solutions to telecommunications carriers and enterprises to deploy, manage and deliver data storage, voice and video services in metropolitan areas. Its optical transmission solutions are based on wavelength division multiplexing (WDM) technology. Its Ethernet-optimized transmission solutions for fiber- or copper-based lines are used to provide access for enterprises into a carrier's network. Its systems are used by telecommunications services providers, companies, universities and government agencies worldwide. It sells its product portfolio both directly and through an international network of distribution partners. Its optical and Ethernet-based network solutions have been deployed by more than 250 carriers and more than 10,000 enterprises. As of December 31, 2012, the Company had 13 wholly owned subsidiaries across Europe, Asia, North and Latin America. Advisors' Opinion:- [By Adrian Day]
Adrian Day: Yes, yes, I like the concept of looking up the secondary plays. I mean, you know we own Altius (ALS) for example, rather than Alderon (ADV). Altius owns 30% of Alderon, that is more diversified, has a better balance sheet. If Alderon succeeds, Atius will succeed.
No comments:
Post a Comment